Hesperidin is found in citrus fruits (for example oranges). It is a dietary supplement used to improve blood flow in the body. It may also be used to treat hemorrhoids. Fibroid tumors in the uterus, endometriosis, and premenstrual syndrome may improve with hesperidin.
Other names for hesperidin include: hesperin methyl-chalcone
Ask your doctor, nurse, or pharmacist if you need more information about this medicine or if any information in this leaflet concerns you.
Tell your doctor if you
Talk with your doctor, pharmacist, or nurse about how much Hesperidin you should take. The amount depends on the strength of the medicine and the reason you are taking Hesperidin. If you are using this medicine without instructions from your caregiver, follow the directions on the label. Do not take more Hesperidin or take it more often than what is written on the directions.
Keep all medicine locked up and away from children. Store medicine away from heat and direct light. Do not store your medicine in the bathroom, near the kitchen sink, or in other damp places. Heat or moisture may cause the medicine to break down and not work the way it should work. Throw away medicine that is out of date or that you do not need. Never share your medicine with others.
Hesperidin may interact with other medicines you may be taking. Talk with your doctor, pharmacist, or nurse before taking hesperidin with any other medicine.
Stop taking your medicine right away and talk to your doctor if you have any of the following side effects.
You may have the following side effects, but this medicine may also cause other side effects. Tell your doctor if you have side effects that you think are caused by this medicine.
1. Allegra C, Bartolo M Jr, Carioti B et al: An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency. Int J Microcirc Clin Exp 1995; 15(suppl 1):50-54.
2. Balas P & Pagratis N: Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency. Int Angiol 1989; 8(suppl 4):51-52.
3. Buckshee K, Takkar D & Aggarwal N: Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynecol Obstet 1997; 57(2):145-151.
4. Cospite M: Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994; 45(6 pt 2):566-573.
5. Cospite M & Dominici A: Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency: advantages of the new micronized form. Int Angiol 1989; 8(suppl 4):61-65.
6. Daftary SN, Irani JS & Tsouderos Y: The therapeutic activity of micronized flavonoid fraction (Daflon 500 mg(R))in IUCD-induced bleeding. Drugs Today 1995; 31(suppl E):41-45.
7. Galley P & Thiollet M: A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S-5682) in the treatment of symptomatic capillary fragility. Int Angiol 1993; 12(1):69-72.
8. Godeberge P: Daflon 500 MG(R): international assessment of therapeutic interest for hemorrhoids. Drugs Today 1995; 31(suppl E):57-62.
9. Guillot B, Guilhou JJ, de Champvallins M et al: A long term treatment with a venotropic drug: results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency. Int Angiol 1989; 8(suppl 4):67-71.
10. Ho YH, Foo CL, Seow-Choen F et al: Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy. Br J Surg 1995; 52(8):1034-1035.
11. Ibegbuna V, Nicolaides AN, Sowade O et al: Venous elasticity after treatment with Daflon 500 mg. Angiology 1997; 48(1):45-49.
12. Meyer OC: Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 1994; 45(6 pt 2):579-584.